YOU ARE ABOUT TO EXIT A US HEMANEXT CORPORATE WEBSITE FOR A GLOBAL HEMANEXT ONE PRODUCT WEBSITE
Please be aware that the website you have requested is intended for the residents of countries in the European Union. The site may contain information on products or uses of those products that are not cleared, approved, or otherwise authorized in all countries or regions, including the US Food & Drug Administration.
WITH DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?
Sickle Cell Disease (SCD) Affects Over 20M Worldwide, including 100K Americans1,2 LEXINGTON, MA and SAN FRANCISCO, CA – Jul 28, 2021 – Hemanext Inc. a privately held, US-based medical technology company dedicated to improving the quality, safety, efficacy, and cost of...
Connect with Hemanext virtual booth at the 36th International Congress of Society of Blood Transfusions (ISBT). Learn about: Blood quality and potential impact on transfusion outcomes Potential benefits of hypoxic storage Hemanext’s vision to create a world with...
In Commemoration of Jimmy Devarie Conde (1969 – 2020) With deep sadness, we inform you of the sudden passing on November 5th of Jimmy Devarie, Plant Manager of the NHS Manufacturing facility. Jimmy was admired, respected, and loved by his team and colleagues here at...
PURPOSE Hemanext is committed to conducting honest, truthful, and reverent research activities, which are consistent with its Mission Statement. Hemanext assures objectivity of its research by maintaining that its Public Health Service (“PHS”), including the National...
